Forte Biosciences rises after saying skin disease trial data will be released in Sept
17/08/2021 11:46
** Shares of co developing biotherapeutics for skin diseases
FBRX.O rise 14.7% to $27.3 premarket
** Co said late Monday it expects to announce on Sept. 7
topline data from mid-stage trial of its lead drug FB-401 for
the treatment of atopic dermatitis urn:newsml:reuters.com:*:nBwbGF5fca
** FB-401 is the only drug in FBRX's pipeline
** Up to Monday's close, stock had fallen ~35% YTD
(Reporting by Dania Nadeem)